Halozyme Therapeutics
San Diego, California, United States · Biopharma, Biotechnology, Health Care
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 468
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (HALO)
- Website
- halozyme.com
- Company page
Recent activity at Halozyme Therapeutics
- : SEC 8-K (5.02): On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc., filling a vacancy in the class of directors with terms extending to the annual meeting of stockholders in 2029. Mr. Daly will receive compensation that includes cash retainers for his Board service, as well as restricted stock and stock option awards in accordance with the company's non-employee director compensation program. This development reflects a strategic enhancement to the board, potentially bringing new expertise and perspectives that could benefit the company.
- : SEC 8-K (1.01): On September 22, 2026, Halozyme Therapeutics, Inc. entered into a material definitive agreement by completing the sale of $1,500 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, which includes $200 million from an option exercised by the initial purchasers. The net proceeds from the offering amount to approximately $1,471.1 million after costs, with about $187.5 million allocated for Capped Call Transactions and plans to repurchase $151.7 million of 2027 Notes and $220 million of 2028 Notes totaling approximately $652.5 million for a comprehensive strategic financial maneuver. This offers significant leverage in managing existing debt while maintaining corporate flexibility, as these transactions are expected to enhance the capital structure of the company.
- : SEC 8-K (8.01): On September 17, 2026, Halozyme Therapeutics, Inc. announced the pricing of its offering of $1.3 billion aggregate principal amount of convertible senior notes due 2033. This pricing includes a 13-day option granted to the initial purchasers to buy up to an additional $200 million in notes. The notes are being sold solely to parties deemed 'qualified institutional buyers' under Rule 144A of the Securities Act of 1933. This significant capital-raising event is intended to provide the company with financing to support its strategic initiatives and operations moving forward.
- : SEC 8-K (8.01): On September 16, 2026, Halozyme Therapeutics, Inc. announced its proposal to offer $1.05 billion aggregate principal amount of convertible senior notes due 2033, subject to market conditions. Additionally, the company intends to allow the initial purchasers a 13-day option to buy up to an extra $150 million of these Convertible Notes. This strategic move aims to strengthen their capital structure and provide additional financial flexibility for future business initiatives. The issuance could impact the company’s debt profile and financing conditions going forward.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): On June 30, 2026, Halozyme Therapeutics, Inc. announced the departure of Cortney Caudill, who served as the Company's Senior Vice President and Chief Operating Officer. The company expressed gratitude for Ms. Caudill's contributions during her tenure. This change in the senior management structure may indicate a strategic shift for Halozyme as they adapt their leadership to better align with future goals.
- : Halozyme Appoints David Ramsay as President Drug Delivery
- : Halozyme Partners with GSK to Enhance Subcutaneous Delivery of Oncology Drugs
- : SEC 8-K (5.02): On April 30, 2026, Halozyme Therapeutics, Inc. announced the appointment of Darren Snellgrove as the new Chief Financial Officer (CFO), effective June 8, 2026. Mr. Snellgrove previously held various finance leadership roles at Johnson & Johnson, including CFO of their Pharmaceutical sector. His annual salary as CFO will be $670,000, with a bonus target of 50% of his base salary prorated for 2026. He will receive significant equity awards upon joining, including $7,200,000 in total value comprised of $3,200,000 in restricted stock units (RSUs) and $4,000,000 in stock options, designed to compensate for forfeited equity from J&J. This hiring aligns with the company’s strategy to strengthen its executive leadership and financial oversight.
- : SEC 8-K (5.03): On April 22, 2026, Halozyme Therapeutics, Inc. amended its Bylaws to revise Section 2.5, allowing directors to be removed at any time, with or without cause, by a majority vote of the shares entitled to vote. Additionally, Section 1.12 was amended to clarify that actions which may be taken at stockholders' meetings cannot occur without an actual meeting, aligning with the provisions outlined in the Certificate of Incorporation. These changes enhance the governance structure of the company and provide greater flexibility in board management. Such amendments could impact the dynamics of control and decision-making within the organization.
Leadership
- Vidhyadhar Barve, Senior Director, IT Business Partner, HR & GxP Systems
- Richard Kurtz, Vice President Corporate Development, M&A
- David Ramsay, President
- Paul Spence, Chief Commercial Officer
- Cortney Caudill, Chief Operating Officer
Verified email and direct lines for Halozyme Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Halozyme Therapeutics files 1 employee benefit plan with the U.S. Department of Labor. The next plan year renews in Dec 2026.
Halozyme Therapeutics in the news
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - PR Newswire (Sep 17, 2026)
- Halozyme Announces Appointment of Jim Daly to its Board of Directors - PR Newswire (Sep 30, 2026)
- Halozyme Appoints David Ramsay as President Drug Delivery - PR Newswire (Jun 30, 2026)
- Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery - PR Newswire (Nov 18, 2025)
- Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets - PR Newswire (Oct 07, 2026)
- Halozyme Appoints Darren Snellgrove as Chief Financial Officer - PR Newswire (Apr 30, 2026)
- Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PR Newswire (Jun 15, 2026)
- Halozyme Completes Antares Pharma Acquisition - PR Newswire (May 24, 2022)
Companies similar to Halozyme Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
- MacroGenics · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Everest Medicines · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
- TerSera · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Manufacturing, Pharmaceutical
About Halozyme Therapeutics: questions and answers
What does Halozyme Therapeutics do?
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies.
Where is Halozyme Therapeutics headquartered?
Halozyme Therapeutics is headquartered in San Diego, California, United States.
How many employees does Halozyme Therapeutics have?
Halozyme Therapeutics has about 468 employees.
Who leads Halozyme Therapeutics?
Richard Kurtz is a Vice President Corporate Development, M&A at Halozyme Therapeutics.
What is the latest news on Halozyme Therapeutics?
On Sep 28, 2026, SEC 8-K (5.02): On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc., filling a vacancy in the class of directors with terms extending to the annual meeting of stockholders in 2029. Mr. Daly will receive compensation that includes cash retainers for
Is Halozyme Therapeutics a public company?
Yes. Halozyme Therapeutics is publicly traded under the ticker HALO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy